Suppr超能文献

即饮型肠道准备剂的疗效、安全性及耐受性:一项III期、评估者盲法研究的年龄亚组分析

Efficacy, safety, and tolerability of a ready-to-drink bowel preparation: subanalysis by age from a phase III, assessor-blinded study.

作者信息

Hookey Lawrence, Bertiger Gerald, Johnson Kenneth Lee, Boules Mena, Ando Masakazu, Dahdal David N

机构信息

Department of Medicine, Queen's University, Kingston, ON, Canada.

Hillmont GI, 1811 Bethlehem Pike, Bldg C-300, Flourtown, PA 19031, USA.

出版信息

Therap Adv Gastroenterol. 2020 Feb 7;13:1756284820902878. doi: 10.1177/1756284820902878. eCollection 2020.

Abstract

BACKGROUND

The incidence and mortality of colorectal cancer (CRC) increase with age and, therefore, it is recommended that adults undergo regular CRC screening, ideally by colonoscopy, with some new guidelines recommending screening begin at 45 years. Effective bowel preparation is a critical step to a successful colonoscopy. Of concern is that older adults may have poorer quality of bowel preparation or reduced tolerability for the bowel preparation. Here, we performed a secondary analysis for the effect of age on the efficacy, tolerability, and safety of ready-to-drink sodium picosulfate, magnesium oxide, and citric acid (SPMC oral solution) bowel preparation.

METHODS

A phase III, randomized, assessor-blinded, multicenter, non-inferiority study was conducted comparing split-dose, low-volume SPMC oral solution with split-dose, low-volume sodium picosulfate, magnesium oxide, and citric acid powder for oral solution. A secondary analysis was performed to assess efficacy, safety, and tolerability of SPMC oral solution by age group (<50 years, 50-64 years, ⩾65 years). The prespecified primary efficacy endpoint ('responders') was the proportion of participants with 'excellent' or 'good' ratings on a modified Aronchick Scale (AS). Secondary efficacy outcomes were the quality of cleansing of the right colon as assessed by the Boston Bowel Preparation Scale (BBPS); as well as selected findings from the Mayo Clinic Bowel Prep Tolerability Questionnaire. Safety assessments included adverse events (AEs) and laboratory evaluations.

RESULTS

Within age groups, at least 83.9% of participants were responders by the AS, and at least 91.1% of participants were responders by the BBPS in the right colon. On both scales, responder rates were highest in the youngest age group and decreased with increasing age. Greater than 88% of participants in any age group found the preparation 'easy' or 'acceptable' to ingest, with rates of 'easy' being highest in the oldest age group. No new safety signals were seen in any age group. The most commonly reported drug-related, treatment-emergent AEs were, by ascending age group, nausea (7.0%, 3.2%, 0.8%), headache (4.2%, 2.8%, 1.6%) and vomiting (2.8%, 1.2%, 0.8%).

CONCLUSION

Ready-to-drink SPMC oral solution showed good efficacy of overall colon cleansing and tolerability in adults across different age groups, including those ⩾65 years.ClinicalTrials.gov identifier: NCT03017235.

摘要

背景

结直肠癌(CRC)的发病率和死亡率随年龄增长而升高,因此建议成年人定期进行CRC筛查,理想方式是结肠镜检查,一些新指南建议从45岁开始筛查。有效的肠道准备是成功进行结肠镜检查的关键步骤。令人担忧的是,老年人的肠道准备质量可能较差,或者对肠道准备的耐受性降低。在此,我们对年龄对即饮型聚乙二醇电解质散(SPMC口服溶液)肠道准备的有效性、耐受性和安全性的影响进行了二次分析。

方法

进行了一项III期、随机、评估者盲法、多中心、非劣效性研究,比较分剂量、低容量的SPMC口服溶液与分剂量、低容量的聚乙二醇电解质散口服粉末。通过年龄组(<50岁、50 - 64岁、⩾65岁)对SPMC口服溶液的有效性、安全性和耐受性进行二次分析。预先设定的主要疗效终点(“反应者”)是在改良的阿隆奇克量表(AS)上获得“优秀”或“良好”评分的参与者比例。次要疗效结果是通过波士顿肠道准备量表(BBPS)评估的右半结肠清洁质量;以及梅奥诊所肠道准备耐受性问卷的选定结果。安全性评估包括不良事件(AE)和实验室评估。

结果

在各年龄组中;根据AS,至少83.9%的参与者为反应者,根据BBPS,右半结肠中至少91.1%的参与者为反应者。在两个量表上,反应者率在最年轻年龄组中最高,并随年龄增长而降低。任何年龄组中超过88%的参与者认为该制剂“易于”或“可接受”服用,“易于”服用的比例在最年长年龄组中最高。在任何年龄组中均未发现新的安全信号。按年龄组升序排列,最常报告的与药物相关的、治疗中出现的AE为恶心(7.0%、3.2%、0.8%)、头痛(4.2%、2.8%、1.6%)和呕吐(2.8%、1.2%、0.8%)。

结论

即饮型SPMC口服溶液在不同年龄组的成年人中,包括⩾65岁的成年人中,显示出良好的全结肠清洁效果和耐受性。

临床试验注册号

NCT03017235

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a30d/7011337/82663c90459a/10.1177_1756284820902878-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验